

Centre for AIDS Reagents

Data Sheet

NAME: Pseudotyped virus HIV -AC10.0.29(pSG3?env)/293T/17

REPOSITORY REFERENCE: ARP1136 (200903175098P)

HARVEST DATE: 20/MAR/09

DESCRIPTION: HIV-1 Env-pseudotyped virus for assessing neutralizing antibody response in the TZM-bl assay

HOST CELLS: 293T/17 (P31)

ENVELOPE PLASMID: AC10.0.29
Tier: 2
Clade: B
Country of origin: USA
Fiebig Stage: III
Mode of Transmission: M-M
Accession number: AY835446

BACKBONE PLASMID: pSG3 delta env (was derived from pSG3.1 by partial SpeI digestion, Klenow filling of the 3' recessed ends and religation. This introduced a four nucleotide insertion mutation (CTAG) in env and a translation stop codon after amino acid residue 142).

Accession number: L02317

RECOMMENDED VIRUS DILUTION 1:9
IN NEUTRALISING ANTIBODY 1:9 (1x thawed)
IN TZM-BL CELLS:

PROJECTED RLU EQUIVALENCE 175.000
IN TZM-BL CELLS:

National Institute for Biological Standards and Control – Assuring the quality of biological medicines

Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom
Tel +44 (0)1707 641000 Fax +44 (0)1707 641050 www.nibsc.ac.uk
A World Health Organization Laboratory for Biological Standards

PRESENTATION:	1 ml
STORAGE:	-80°C
BIOHAZARD:	Biosafety Level II or III as HIV-1 Env-pseudoviruses are revertible to replication competent HIV
SOURCE:	Env plasmid was provided by David Montefiori and the backbone plasmid was contributed by John Kappes and Xiaoyun Wu.

HIV pseudotyped virus was produced by Stefanie Koch, Andreas Meyerhans and Hagen von Briesen at HSC (HIV Specimen Cryorepository) under GCLP conditions.

REFERENCES:

Li, M., F. Gao, J.R. Mascola, L. Stamatatos, V.R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K.M. Greene, M. Bilska, D.L. Kothe, J.F. Salazar-Gonzalez, X. Wei, J.M. Decker, B.H. Hahn, and D.C. Montefiori. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *J. Virol.*, 79:10108-10125.

Wei S, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, and Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother* 46: 1896-1905, 2002.

Wei X, Decker JM, Wang S Hui H, Kappes JC, Wu X, Salazar-Gonzales JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD and Shaw GM. Antibody neutralization and escape by HIV-1. *Nature* 422: 307-312, 2003.

LEGAL NOTE:

Consultation needed

The HIV pseudovirus production and distribution project is a collaborative effort of the Comprehensive Antibody Vaccine Immune Monitoring Center (CA-VIMC) (PI David Montefiori) and the HIV Specimen Cryorepository (HSC) (PI Hagen von Briesen) within the Collaboration for AIDS Vaccine Discovery (CAVD) (founded by the Bill and Melinda Gates foundation).

Production, quality control and distribution of HIV-1 Env-pseudoviruses is conducted by the HSC (Stefanie Koch, Hagen von Briesen). HIV Env-pseudoviruses are provided on a collaborative basis with Stefanie Koch, Andreas Meyerhans and Hagen von Briesen.

ACKNOWLEDGEMENTS:

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website in the “Acknowledgements” section at:

www.nibsc.ac.uk/spotlight/centre_for_aids_reagents.aspx

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)